Description: Telix Pharmaceuticals Limited, an oncology company, develops molecularly targeted radiation products for unmet needs in cancer care in Australia. Its products include TLX101, which is in Phase I/II clinical trial for the treatment of glioblastoma; TLX250, which is in Phase II for the diagnosis and treatment of renal cancer; TLX250-CDx, which is in Phase III for the imaging of clear cell renal cell cancer; TLX591, which is in pre-Phase III for the treatment of metastatic castrate-resistant prostate cancer; and TLX591-CDx, which is in Phase III for the imaging of prostate cancer. The company has collaboration agreements with Radboud University, University of Nantes/ARRONAX, University of Melbourne Osaka University, Winship Cancer Institute of Emory University, Merck Healthcare KGaA, and Memorial Sloan Kettering, as well as the Institute for Radiation Sciences, Osaka University and the Department of Nuclear Medicine, and Tracer Kinetics at Osaka University Graduate School of Medicine. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.
Home Page: telixpharma.com
55 Flemington Road
North Melbourne,
VIC
3051
Australia
Phone:
61 3 3093 3897
Officers
| Name | Title |
|---|---|
| Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA | Co-Founder, Group MD, CEO & Exec. Director |
| Dr. Andreas Kluge M.D., Ph.D. | Chief Medical Advisor & Director |
| Mr. Darren Smith B.Bus., FCPA, M.B.A. | Group Chief Financial Officer |
| Dr. Michael Wheatcroft B.Sc., BSc(Hons), Ph.D., Ph.D., (Cantab) | Chief Scientist |
| Ms. Kyahn Williamson | Sr. VP of Corp. Communications & Investor Relations |
| Ms. Melanie Farris (AGIA, ACG, ACIS) BComn, B.Com., GradDip, M.A.I.C. | Sr. VP of Global Governance, Risk & Compliance |
| Ms. Lena Moran-Adams | Gen. Counsel |
| Ms. Amanda Griffin | Communications Mang. |
| Mr. Christian Davis | VP Sales and Marketing, EMEA |
| Ms. Meredith Crowe | Interim Sr. VP of Global People & Culture |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 21.5517 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 21.1586 |
| Price-to-Sales TTM: | 52.2133 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |